EUVIMEDEUVIMED entdecken
Open Access

Sequential EGFR inhibition sensitizes glioblastoma to temozolomide

Xiaozhou Yu, Runxin Wu, Shi-Yuan Cheng

Trends in Pharmacological Sciences · 2026-09 · 47 (9) · 952-954

DOI: 10.1016/j.tips.2026.07.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Trends in Pharmacological Sciences, 2026-09. Verfasst von Xiaozhou Yu und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Ken & Ruth Davee Department of Neurology, The Lou and Jean Malnati Brain Tumor Institute, the Robert H. Lurie Comprehensive Cancer Center, Simpso…. Hauptthemen laut MEDLINE: ErbB Receptors, Glioblastoma, Dacarbazine, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, National Institutes of Health, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsGlioblastomaDacarbazineBrain NeoplasmsAntineoplastic Agents, AlkylatingProtein Kinase InhibitorsTemozolomideHumansAnimalsO(6)-Methylguanine-DNA MethyltransferaseDNA Modification Methylases

Stichwörter der Autor:innen

O(6)-methylguanine–DNA methyltransferaseactivator protein-1miR-616nuclear factor-κB

Substanzen

TemozolomideErbB ReceptorsDacarbazineAntineoplastic Agents, AlkylatingO(6)-Methylguanine-DNA MethyltransferaseProtein Kinase InhibitorsDNA Modification Methylases

Autor:innen und Institutionen

  • The Ken & Ruth Davee Department of Neurology, The Lou and Jean Malnati Brain Tumor Institute, the Robert H. Lurie Comprehensive Cancer Center, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg…

Förderung

  • NINDS NIH HHS
  • National Institutes of Health
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Yu, X., Wu, R., & Cheng, S. Y. (2026). Sequential EGFR inhibition sensitizes glioblastoma to temozolomide. Trends in Pharmacological Sciences, 47(9), 952-954. https://doi.org/10.1016/j.tips.2026.07.010

Vancouver

Yu X, Wu R, Cheng SY. Sequential EGFR inhibition sensitizes glioblastoma to temozolomide. Trends in Pharmacological Sciences. 2026;47(9):952-954. doi:10.1016/j.tips.2026.07.010

BibTeX
@article{Yu2026,
  author = {Yu, Xiaozhou and Wu, Runxin and Cheng, Shi-Yuan},
  title = {Sequential EGFR inhibition sensitizes glioblastoma to temozolomide},
  journal = {Trends in Pharmacological Sciences},
  year = {2026},
  volume = {47},
  number = {9},
  pages = {952--954},
  doi = {10.1016/j.tips.2026.07.010}
}
Kostenlos starten →